eTumorType, An Algorithm of Discriminating Cancer Types for Circulating Tumor Cells or Cell-free DNAs in Blood
暂无分享,去创建一个
[1] S. Gabriel,et al. Pan-cancer patterns of somatic copy-number alteration , 2013, Nature Genetics.
[2] Edwin Wang,et al. Understanding genomic alterations in cancer genomes using an integrative network approach. , 2013, Cancer letters.
[3] N. Rosenfeld,et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA , 2013, Nature.
[4] Zhihai Peng,et al. CD133+CD54+CD44+ circulating tumor cells as a biomarker of treatment selection and liver metastasis in patients with colorectal cancer , 2016, Oncotarget.
[5] Oleksii Nikolaienko,et al. Concentration and Methylation of Cell-Free DNA from Blood Plasma as Diagnostic Markers of Renal Cancer , 2016, Disease markers.
[6] Ash A. Alizadeh,et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage , 2013, Nature Medicine.
[7] Gudrun Schleiermacher,et al. Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in Neuroblastoma , 2016, Clinical Cancer Research.
[8] Klaus Pantel,et al. Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer , 2016, Oncotarget.
[9] Ali Bashashati,et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling , 2013, The Journal of pathology.
[10] Jinfeng Zou,et al. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer. , 2016, JAMA oncology.
[11] C. Lim,et al. Isolation and retrieval of circulating tumor cells using centrifugal forces , 2013, Scientific Reports.
[12] Rachael P. Huntley,et al. QuickGO: a web-based tool for Gene Ontology searching , 2009, Bioinform..
[13] Edwin Wang,et al. Cancer systems biology in the genome sequencing era: part 1, dissecting and modeling of tumor clones and their networks. , 2013, Seminars in cancer biology.
[14] E. Wang,et al. Predictive genomics: a cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data. , 2014, Seminars in cancer biology.
[15] Michael J. Powell,et al. Genetic alteration and mutation profiling of circulating cell-free tumor DNA (cfDNA) for diagnosis and targeted therapy of gastrointestinal stromal tumors , 2016, Chinese journal of cancer.
[16] Obi L. Griffith,et al. SciClone: Inferring Clonal Architecture and Tracking the Spatial and Temporal Patterns of Tumor Evolution , 2014, PLoS Comput. Biol..
[17] A. McKenna,et al. Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.
[18] Benjamin J. Raphael,et al. Pan-Cancer Network Analysis Identifies Combinations of Rare Somatic Mutations across Pathways and Protein Complexes , 2014, Nature Genetics.
[19] Q. Cui,et al. Identification of high-quality cancer prognostic markers and metastasis network modules , 2010, Nature communications.
[20] Leo Breiman,et al. Random Forests , 2001, Machine Learning.
[21] Mark Culp,et al. and Development , 1998 .
[22] Matthew Rabinowitz,et al. Detection of Clonal and Subclonal Copy-Number Variants in Cell-Free DNA from Patients with Breast Cancer Using a Massively Multiplexed PCR Methodology , 2015, Translational oncology.
[23] A. Børresen-Dale,et al. The Life History of 21 Breast Cancers , 2012, Cell.
[24] Edwin Wang,et al. Signaling network assessment of mutations and copy number variations predict breast cancer subtype-specific drug targets. , 2013, Cell reports.
[25] Jorge S. Reis-Filho,et al. Going with the Flow: From Circulating Tumor Cells to DNA , 2013, Science Translational Medicine.
[26] Aviv Regev,et al. Whole exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer , 2014, Nature Biotechnology.
[27] Jaafar Bennouna,et al. Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients. , 2013, Lung cancer.
[28] Sabine Riethdorf,et al. High‐resolution analyses of copy number changes in disseminated tumor cells of patients with breast cancer , 2012, International journal of cancer.
[29] Bert Vogelstein,et al. DETECTION OF CIRCULATING TUMOR DNA IN EARLY AND LATE STAGE HUMAN MALIGNANCIES , 2014 .
[30] J. Mesirov,et al. GenePattern 2.0 , 2006, Nature Genetics.
[31] Peter Ulz,et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. , 2013, Cancer research.
[32] B. Coe,et al. DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers , 2008, Oncogene.
[33] Juancarlos Chan,et al. Gene Ontology Consortium: going forward , 2014, Nucleic Acids Res..
[34] Nuria Jordana Ariza,et al. Usefulness of circulating free DNA for monitoring epidermal growth factor receptor mutations in advanced non-small cell lung cancer patients: a case report. , 2016, Translational lung cancer research.
[35] Marius Ilie,et al. Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? , 2014, Annals of translational medicine.
[36] M. Ashburner,et al. Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.
[37] Koichi Goto,et al. Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[38] Edwin Wang,et al. Cancer systems biology in the genome sequencing era: part 2, evolutionary dynamics of tumor clonal networks and drug resistance. , 2013, Seminars in cancer biology.
[39] Caroline Seynaeve,et al. Gene expression profiles of circulating tumor cells versus primary tumors in metastatic breast cancer. , 2015, Cancer letters.
[40] G. Getz,et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.